Vivo Capital LLC boosted its stake in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 123.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,970,152 shares of the company's stock after buying an additional 5,500,000 shares during the period. Unicycive Therapeutics accounts for approximately 0.9% of Vivo Capital LLC's portfolio, making the stock its 27th largest position. Vivo Capital LLC owned 9.61% of Unicycive Therapeutics worth $7,918,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of UNCY. Virtu Financial LLC grew its position in Unicycive Therapeutics by 566.8% during the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock valued at $30,000 after purchasing an additional 62,881 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Unicycive Therapeutics during the third quarter valued at approximately $29,000. Finally, Geode Capital Management LLC increased its position in shares of Unicycive Therapeutics by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after acquiring an additional 122,089 shares in the last quarter. 40.42% of the stock is currently owned by hedge funds and other institutional investors.
Unicycive Therapeutics Price Performance
UNCY stock remained flat at $0.64 during midday trading on Friday. The company's stock had a trading volume of 228,815 shares, compared to its average volume of 1,455,506. The company has a market capitalization of $76.61 million, a price-to-earnings ratio of -0.66 and a beta of 2.15. Unicycive Therapeutics, Inc. has a 1-year low of $0.20 and a 1-year high of $1.29. The business has a 50 day moving average price of $0.58 and a 200 day moving average price of $0.59.
Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). On average, analysts expect that Unicycive Therapeutics, Inc. will post -0.23 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Guggenheim started coverage on Unicycive Therapeutics in a research report on Monday, April 21st. They issued a "buy" rating and a $6.00 price objective on the stock. HC Wainwright restated a "buy" rating and issued a $7.50 price target on shares of Unicycive Therapeutics in a research note on Friday, April 11th.
Get Our Latest Research Report on Unicycive Therapeutics
About Unicycive Therapeutics
(
Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Featured Articles
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
